Aurobindo Pharma Ltd vs Sakar Healthcare Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 18, 2026

Key Highlights

The Latest Trading Price of Aurobindo Pharma Ltd is ₹ 1501 as of 18 May 15:30 . The P/E Ratio of Aurobindo Pharma Ltd changed from 9.7 on March 2021 to 19.3 on March 2025 . This represents a CAGR of 14.75% over 5 yearsThe P/E Ratio of Sakar Healthcare Ltd changed from 16.5 on March 2021 to 26.6 on March 2025 . This represents a CAGR of 10.02% over 5 years The Market Cap of Aurobindo Pharma Ltd changed from ₹ 51653 crore on March 2021 to ₹ 67951 crore on March 2025 . This represents a CAGR of 5.64% over 5 yearsThe Market Cap of Sakar Healthcare Ltd changed from ₹ 176.64 crore on March 2021 to ₹ 464.72 crore on March 2025 . This represents a CAGR of 21.34% over 5 years The revenue of Aurobindo Pharma Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 8833 crore. This represent the decline of -100% The revenue of Sakar Healthcare Ltd for the Mar '26 is ₹ 71.27 crore as compare to the Dec '25 revenue of ₹ 70.85 crore. This represent the growth of 0.59% The ebitda of Aurobindo Pharma Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 1896 crore. This represent the decline of -100% The ebitda of Sakar Healthcare Ltd for the Mar '26 is ₹ 26.41 crore as compare to the Dec '25 ebitda of ₹ 19.1 crore. This represent the growth of 38.27% The net profit of Aurobindo Pharma Ltd changed from ₹ 918.22 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% The net profit of Sakar Healthcare Ltd changed from ₹ 2.41 crore to ₹ 11.02 crore over 8 quarters. This represents a CAGR of 113.84% The Dividend Payout of Aurobindo Pharma Ltd changed from 7.53 % on March 2021 to 0 % on March 2025 . This represents a CAGR of -100.00% over 5 yearsThe Dividend Payout of Sakar Healthcare Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Aurobindo Pharma Ltd

Aurobindo Pharma Limited (APL), one of the world's top 5 manufacturers of semi synthetic penicillins was incorporated in December 1986 as a private limited company.
Mr. P.V.Ramaprasad Reddy, Mr. K.Nityananda Reddy and a small, highly committed group of professionals founded it.
APL is developing, manufacturing and marketing active pharmaceutical ingredients (APIs also referred as bulk actives), intermediates and generic formulations.
The company's robust product portfolio is spread over 6 major product areas encompassing (Antibiotics, Anti-Retro Virals, CVS, CNS, Gastroenterologicals, and Anti-Allergics) with around 65 APIs in the non-antibiotics and over 55 APIs in the antibiotic segment and the World Health Organization (WHO), Geneva, has also approved Aurobindo's products.
APL is running with 29 manufacturing plants across the world conforming to GMP/ISO regulations and an extremely well equipped 9 R&D facilities.

About Sakar Healthcare Ltd

Sakar Healthcare Limited was incorporated as a Private Limited Company under the name 'Sakar Healthcare Private Limited on 26th March 2004.
Subsequently, the Company was converted into Public Limited Company on March 27, 2015 and the name of the Company was changed to 'Sakar Healthcare Limited.
The Company is promoted by Sanjay Shah, Rita Shah and Aarsh Shah. The Company is engaged in manufacturing of Pharmaceutical products providing Liquid Orals, Cephalosporin Tablet, Capsule, Dry Powder Syrup, Dry Powder Injections, Liquid Injectables (SVP) in Ampoules and Vials & Lyophilized Injections and Oral Solid Dossages.
It manufactures and markets pharmaceutical formulations relating to analgesics, anti coagulants, anti malarial, anti spasmodic, antianemics, antibiotics, anti-emetics, anti-histamines, bronchodilators, corticosteroids, cough and cold preparations, multivitamins, etc.

FAQs for the comparison of Aurobindo Pharma Ltd and Sakar Healthcare Ltd

Which company has a larger market capitalization, Aurobindo Pharma Ltd or Sakar Healthcare Ltd?

Market cap of Aurobindo Pharma Ltd is 87,776 Cr while Market cap of Sakar Healthcare Ltd is 1,550 Cr

What are the key factors driving the stock performance of Aurobindo Pharma Ltd and Sakar Healthcare Ltd?

The stock performance of Aurobindo Pharma Ltd and Sakar Healthcare Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Aurobindo Pharma Ltd and Sakar Healthcare Ltd?

As of May 18, 2026, the Aurobindo Pharma Ltd stock price is INR ₹1511.3. On the other hand, Sakar Healthcare Ltd stock price is INR ₹696.7.

How do dividend payouts of Aurobindo Pharma Ltd and Sakar Healthcare Ltd compare?

To compare the dividend payouts of Aurobindo Pharma Ltd and Sakar Healthcare Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.